

– To create Wealth
Invest in Health



30 Dec 2022

Introducing

Motilal Oswal S&P BSE Healthcare ETF


(An open ended fund replicating / tracking the S&P BSE Healthcare Total Return Index)

**THINK EQUITY
THINK MOTILAL OSWAL**

INDEX FUNDS
by
MOTILAL OSWAL

— The Covid-19 Catastrophe

Pandemic made us realize importance of health system



'There are decades where nothing happens, and there are weeks where decades happen'


***–Vladmir Lenin
(Former premier)***

Source/ Disclaimer: The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

— Healthcare Sector by the numbers

Domestic healthcare sector on a strong footing

Rising income, increasing awareness, lifestyle diseases and increased access to insurance, suggests that healthcare sector will note robust growth




Source: NITI Ayog, Frost & Sullivan, LSI Financial Services, Deloitte. Bookmyforex for historical USD/INR values & 28/03/2022 value of USD/INR for 2022 F data. Data as per latest available report as of 30 March 2021. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

For Financial Professionals. Proprietary Content. Permission to reprint or distribute any content from this presentation requires the written approval of Motilal Oswal Asset Management Company.

Sector will be aided by increased government spending

The domestic healthcare sector will get shot in the arm as the Government plans to amp up spending and provide healthcare facilities to the economically weaker section



Source/ Disclaimer: indiabudget.gov.in. The above graph is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

India-The pharmacy of the world

Domestic pharma market is pegged at **\$42 Billion** in 2021 and is expected to reach **\$130 Billion** by 2030



Accounts for
50%
of global vaccine
supplies

3rd Largest
market by volume



14th Largest
market by value

Largest
provider of generic
drugs globally



Source/ Disclaimer: IBEF. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.


Inadequate healthcare infrastructure indicates tremendous growth opportunity

India's doctor-population ratio and bed density ratio vis-à-vis other economies is relatively lower indicating strong growth potential

**Doctors
(per 10,000 population) [1]**



Hospital Bed density (per 10,000 population) [2]




Source: [1] WHO World Health Statistics 2020, [2] India bed density is estimated by CRISIL Research, tracking Universal health Coverage- 2017 Global Monitoring Report, World Bank Data base, CRISIL Research. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

— Tailwinds for Diagnostics

- Domestic diagnostic industry estimated at ~\$9 Billion (2020) and is expected to grow at over 10% over next 5 years
- The diagnostics business is asset light model as it operates on hub and spoke model
- Only 20% of total diagnostic services are reimbursed via insurance claims, rest is out of pocket expense
- Inclusion of diagnostic tests under insurance coverage may lead to inflection in growth rate of the industry

India's out of pocket spending is at elevated levels (%)



Source: WHO, Kotak Institutional Equities


Source: Edelweiss Professional Investor Research 2020, Kotak Institutional Equity. The above graph is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

India poised to be an attractive destination for Medical Tourism

- Medical tourism business pegged at \$5 billion in 2020
- Expected to become a \$14 billion business by 2023
- Medical tourism expected to grow at ~21% CAGR between 2020-27

Treatment costs in India well below global costs
Medical tourism Treatment cost (US\$)


Treatment	US	UK	Thailand	Singapore	India
Heart Surgery	100,000	40,000	14,000	15,000	5,000
Bone Marrow Transplant	250,000	290,000	62,000	150,000	30,000
Liver Transplant	300,000	200,000	75,000	140,000	45,000
Knee Replacement	48,000	50,000	8,000	25,000	6,000



India ranked #10th out of the top 46 countries for medical tourism

Source/Disclaimer: Average cost of treatment;- Kotak Institutional Equities, Market size- Trade promotion council of India & Kotak Institutional Equities. #medical tourism Index 2020-2021. The graphic is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

Key Growth Drivers



Source/Disclaimer: *100% FDI permitted under automatic route in the hospital sector. In the pharmaceutical sector, 100% FDI in green field projects and 74% in brownfield projects. The graphic is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

— About Motilal Oswal S&P BSE Healthcare ETF

Motilal Oswal S&P BSE Healthcare ETF



Type of Scheme

An open ended fund replicating/tracking S&P BSE Healthcare Total Return Index



Minimum Application Lot Size

On Exchange – Investors can buy/sell units of the Scheme in round lot of 1 unit and in multiples thereafter

Directly with Mutual Fund – Buy/sell units of the Scheme where the subscription / redemption amount is in excess of INR 25 Crs. However, the same limit is not applicable to Market makers.



Investment Objective

The investment objective of the scheme is to provide returns that, before expenses, correspond to the total returns of the securities as represented by S&P BSE Healthcare TRI, subject to tracking error. However, there is no guarantee or assurance that the investment objective of the scheme will be achieved



Exit Load

Nil



Date of Allotment

29-Jul-2022



Fund Manager

Mr. Swapnil Mayekar &
Mr. Rakesh Shetty (Debt component)



Benchmark

S&P BSE Healthcare TRI



Indicative Total Expense Ratio

Regular- 0.20%

Source/Disclaimer: MOAMC. Data as on 30-Dec-22 Mutual funds are subject to market risk, read all scheme documents carefully

Product Suitability


Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal S&P BSE Healthcare ETF (An open ended fund replicating / tracking the S&P BSE Healthcare Total Return Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Healthcare Total Return Index subject to tracking error Long term capital growth 	<p style="text-align: center;">Fund</p> 	<p style="text-align: center;">S&P BSE Healthcare Total Return Index</p> 

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

About: S&P BSE Healthcare Total Return Index

Index Objective: The S&P BSE Healthcare Total Return Index is designed to provide investors exposure to companies included in the S&P BSE AllCap that are classified as members of the healthcare sector.

Index Methodology Snapshot:




Source/Disclaimer: S&P BSE. Data as on 30-Dec-22 *for detailed index methodology kindly visit <https://www.spglobal.com/spdji/en/>

S&P BSE Healthcare Index snapshot


Top 10 Constituents

S. No.	Constituent Name	Weight
1	Sun Pharmaceutical Industries Ltd	17.3%
2	Cipla Ltd/India	9.3%
3	Dr Reddy'S Laboratories Ltd	8.2%
4	Apollo Hospitals Enterprise Ltd	7.2%
5	Divi'S Laboratories Ltd	6.9%
6	Max Healthcare Institute Ltd	5.2%
7	Lupin Ltd	2.8%
8	Torrent Pharmaceuticals Ltd	2.4%
9	Fortis Healthcare Ltd.	2.4%
10	Laurus Labs Ltd	2.4%
--	Total	64.1%

Basic Industry (AMFI) Coverage by Mcap (%)



SEBI Size Coverage by weight (%)



Total number of constituents = 97

Source/Disclaimer: S&P BSE. Data as of 30-Sep-2022. Sectors – Basic Industry classification as per AMFI Industry Classification. The stocks/sectors mentioned above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The stock may or may not be part of our portfolio/strategy/ schemes. It should not be construed as investment advice to any party. Past performance may or may not be sustained in future.

— Sneak Peak into industries forming part of the index

Pharmaceutical


Includes manufacturing, extraction, processing, purification and packaging
Eg – Sun Pharma

Hospital

Includes healthcare centres, district hospital, general hospital & nursing homes. Eg – Apollo Hospital

Medical Equipment

Includes medical equipment and supplies. . Eg – Poly Medicare



Specialty Chemical

Includes manufacturing, extraction, processing, purification and packaging
Eg- Aarti Drugs Ltd


Diagnostic

Includes businesses and laboratories with analytical or diagnostic services.
Eg – Lal Path labs

Source/ Disclaimer: The stocks/sectors mentioned above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The stock may or may not be part of our portfolio/strategy/ schemes. It should not be construed as investment advice to any party

Historical Performance


S&P BSE Healthcare Total Return Index has significantly outperformed the broad market over the last 15 years



Source/Disclaimer: S&P BSE. Performance as of close of 31-Dec-07 to 30-Dec-22 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Calendar Year Performance

S&P BSE Healthcare Index has outperformed against S&P BSE All Cap Index in **8** out of last **15** calendar years



Source/Disclaimer: S&P BSE. Performance as of close of 31-Dec-07 to 30-Dec-22 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Outperformance to broader market

Data Label		1 year	3 year	5 year	10 year	15 year
S&P BSE Healthcare TRI	CAGR	-11.5%	20.5%	10.0%	11.7%	12.5%
S&P BSE AllCap TRI		4.7%	18.2%	11.6%	14.0%	8.8%
S&P BSE Healthcare TRI	Annualised Volatility	15.4%	20.1%	18.6%	17.9%	18.4%
S&P BSE AllCap TRI		17.4%	21.6%	18.8%	16.8%	20.9%
S&P BSE Healthcare TRI	Risk Adjusted Returns	-0.745	1.019	0.535	0.653	0.678
S&P BSE AllCap TRI		0.271	0.842	0.615	0.836	0.422

Source/Disclaimer: S&P BSE: Performance as of close of 31-Dec-07 to 30-Dec-22. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy.

Index SIP returns



S&P BSE Healthcare TRI	1 Year	3 Year	5 Year	7 year	10 Year
Returns	-3.8%	8.8%	12.5%	10.1%	9.5%
Amount Invested	1,20,000	3,60,000	6,00,000	8,40,000	12,00,000
Market Value	1,17,566	4,11,043	8,21,513	12,02,230	19,61,092

Data as of close of Dec 30, 2022 For SIP returns, monthly investment of INR 10,000/- invested on the first business day of every month has been considered. Performance is calculated using Total Return Index, with zero cost/expenses. Past performance may or may not be sustained in the future

Source/Disclaimer: niftyindices, S&P BSE, MOAMC Research. Performance as of close of 01-Apr-05 to 30-Dec-22. All Performance numbers in CAGR. Bear market defined as >20% fall from peak to trough. Recovery defined as the recovery from trough to previous peak. Bull market defined as rising market after recovery. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Better odds of double digit returns!




	3 Year Rolling Returns		5 Year Rolling Returns	
	S&P BSE Healthcare TRI	S&P BSE AllCap TRI	S&P BSE Healthcare TRI	S&P BSE AllCap TRI
Average	16.2%	12.1%	14.9%	12.1%
Median	18.4%	12.6%	13.9%	13.0%
Min	-9.8%	-5.9%	-6.4%	-1.8%
Max	43.2%	33.4%	33.8%	24.3%
Returns Range	% of Total Observation			
Negative	18.6%	5.0%	5.6%	1.1%
0% to 10%	5.9%	31.1%	22.3%	31.2%
10% to 15%	10.2%	28.8%	25.5%	31.8%
15% to 20%	75.5% { 22.6%	64.0% { 21.7%	72.1% { 15.0%	67.8% { 34.3%
Above 20%	42.7%	13.4%	31.6%	1.7%

Source/Disclaimer: S&P BSE. 250 trading days assumed in one year. S&P BSE. Performance as of close of 16-Dec-05 to 30-Dec-22 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.



Lower drawdowns over last 15 years

As healthcare sector is a defensive play, the S&P BSE Healthcare Index has historically seen smaller drawdowns vs its benchmark



Source/Disclaimer: S&P BSE. Performance as of close of 31-Dec-07 to 30-Dec-22 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Performance across market cycles

Market Cycle	Nifty 50 TRI	S&P BSE Healthcare TRI	S&P BSE AllCap TRI
Bull	28.5%	6.4%	16.5%
Bear	-38.8%	-18.1%	-42.4%
Recovery	34.2%	41.0%	37.9%


- Healthcare sector tends to be a defensive play
- The S&P BSE healthcare Index has historically outperformed the broader benchmarks during Bear and recovery market cycles

Source/Disclaimer: niftyindices, S&P BSE, MOAMC Research. Performance as of close of 01-Apr-05 to 30-Dec-22. All Performance numbers in CAGR. Bear market defined as >20% fall from peak to trough. Recovery defined as the recovery from trough to previous peak. Bull market defined as rising market after recovery. Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

— Comparison peer indices

S&P BSE Healthcare Total Return Index provides broadest exposure


	S&P BSE Healthcare TRI	Nifty Healthcare TRI	Nifty Pharmaceutical TRI
No. of companies	Variable (Currently 97)	Fixed (20)	Fixed (20)
Industry coverage	All 7	2 out of 7	1 out of 7
Coverage of healthcare universe	~99%	~70%	~68%
Largest Industry	Pharmaceutical; 81%	Pharmaceutical; 87%	Pharmaceutical; 100%
Largest stock	Sun Pharmaceutical Ltd. 15.8%	Sun Pharmaceutical Ltd. 20.8%	Sun Pharmaceutical Ltd. 22.4%



Source: spglobal.com; niftyindices.com; Data as on 30-June-22 for BSE Healthcare TRI; S&P BSE Healthcare TRI Index launch date – 25th Feb 22; Nifty Healthcare TRI, 18th November 20; Nifty Pharma TRI, 1 July 2005. . The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Performance over peer indices

S&P BSE Healthcare Index has outperformed Nifty Healthcare Index and Nifty Pharma Index



Source/Disclaimer: S&P BSE, Nifty Indices. Performance as of close of 31-Dec-07 to 30-Dec-22 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Performance over peers



Annualized Returns

Peers	1 year	3 year	5 year	10 year	15 year
S&P BSE Healthcare TRI	-11.50%	20.49%	9.97%	11.67%	12.46%
Nifty Healthcare TRI	-10.11%	19.11%	8.55%	10.05%	11.46%
Nifty Pharma TRI	-10.73%	16.99%	6.28%	8.32%	10.44%
Nifty 50 TRI	5.69%	15.52%	12.85%	13.24%	8.77%

Source/Disclaimer: S&P BSE, Nifty Indices. Performance as of close of 31-Dec-07 to 30-Dec-22 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Why should you invest in Motilal Oswal S&P BSE Healthcare ETF?



One of the fastest growing sectors in India

Has strong tailwinds such as rising healthcare awareness among citizens.

Offers broadest exposure among peer indices.

Defensive play


Source/ Disclaimer: The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

29 For Financial Professionals. Proprietary Content. Permission to reprint or distribute any content from this presentation requires the written approval of Motilal Oswal Asset Management Company.



— Annexure

Historical Industry Breakup




Others = Healthcare service providers, Medical equipment & supplies, Healthcare research, healthcare analytics, healthcare technology etc

Source/Disclaimer: S&P BSE, Nifty Indices. Performance as of close of 31-Dec-18 to 30-Dec-22 . Basic Industry as per AMFI Industry Classification. The industries mentioned above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The sectors may or may not be part of

Exposure to All Caps

S&P BSE Healthcare Index has healthy mix of Large Mid and Small Cap Stocks



Source/Disclaimer: S&P BSE; Data from 30-Sep-18 to 30-Sep-2022. Size classification as per AMFI; . The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Performance vs Nifty 50

Data Label		1 year	3 year	5 year	10 year	15 year
S&P BSE Healthcare TRI	CAGR	-11.5%	20.5%	10.0%	11.7%	12.5%
Nifty 50 TRI		5.7%	15.5%	12.9%	13.2%	8.8%
S&P BSE Healthcare TRI	Annualised Volatility	15.4%	20.1%	18.6%	17.9%	18.4%
Nifty 50 TRI		17.2%	22.5%	19.4%	17.1%	21.6%
S&P BSE Healthcare TRI	Risk Adjusted Returns	-0.745	1.019	0.535	0.653	0.678
Nifty 50 TRI		0.330	0.691	0.664	0.773	0.405

Source/Disclaimer: S&P BSE, Nifty Indices. Performance as of close of 31-Dec-07 to 30-Dec-22 . Performance results have many inherent limitations and no representation is being made that any investor will, or is likely to achieve. Past performance may or may not be sustained in future. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

Existing healthcare funds



Existing passive funds track the Nifty Healthcare Index


Passive Funds				Expense Ratio	
Sr.No	Scheme Name	Inception Date	AUM (in Rs Cr)	Regular	Direct
1	ICICI Pru Healthcare ETF	18-May-21	106	-	0.2
2	Aditya Birla SL Nifty Healthcare ETF	21-Oct-21	26.1	-	0.1
3	Axis Healthcare ETF	17-May-21	19.6	-	0.2

Active Funds				Expense Ratio	
Sr.No	Scheme Name	Inception Date	AUM (in Rs Cr)	Regular	Direct
1	ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund-(G)	13-Jul-18	2316.1	2.1	1.2
2	Mirae Asset Healthcare Fund-Reg(G)	02-Jul-18	1691.6	2.1	0.6
3	SBI Healthcare Opp Fund-Reg(IDCW)	03-Jul-99	1638.3	2.1	1.1
4	DSP Healthcare Fund-Reg(G)	30-Nov-18	1178.6	2.2	0.8
5	UTI Healthcare Fund-Reg(IDCW)	25-Aug-99	706.5	2.5	1.2
6	Tata India Pharma & Healthcare Fund-Reg(G)	28-Dec-15	508.2	2.4	1.0
7	Aditya Birla SL Pharma & Healthcare Fund-Reg(G)	10-Jul-19	470.3	2.6	1.0
8	ITI Pharma & Healthcare Fund-Reg(G)	08-Nov-21	158.9	2.5	0.3
9	Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund-Reg(G)	26-Oct-20	157.1	1.1	0.5
10	IDBI Healthcare Fund-Reg(G)	28-Feb-19	62.3	2.5	1.2

Source: ACE MF. Data as of close of 31-Jul-2022.


Indian healthcare still at a nascent stage

Per capita healthcare spending remains one of the lowest globally
March fiscal year-end, 2021 (USD)




Source: WHO, Kotak Institutional Equities

Spend on healthcare in the consumption mix set to increase (%)



Source: McKinsey, Kotak Institutional Equities

India healthcare market break-up by revenue
March fiscal year-end, 2021 (%)




India needs to add 1.5 mn additional beds over the next decade



Source/Disclaimer: Kotak Institutional Equities; Data as per latest available report as of June 202. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

eHealth- a new norm in post Covid era

On the back of rapid digitization and increased government support **India's eHealth market is estimated to touch \$10.6bn by 2025**



- eHealth includes teleconsulting, e-pharmacies, e-diagnostics and online fitness and wellness
- With dual benefit of lower price and more convenience we may see increased adoption of the services


Source/ Disclaimer: INC42- Decoding ehealth opportunity. Article published on Jan 2021. The above graph is used to explain the concept and is for illustration purpose only and should not used for development or implementation of an investment strategy.

eHealth startups landscape




Source/Disclaimer: INC42. Companies shown above are used to explain the concept and is for illustration purpose only and should not be used for development or implementation of an investment strategy. The company may or may not be part of our portfolio/strategy/ schemes. It should not be construed as investment advice to any party.

Motilal Oswal Passive Fund Offerings



Motilal Oswal Passive Fund Offerings




Motilal Oswal Passive Fund Offerings



Motilal Oswal Passive Fund Offerings

5 Year G-Sec Fund of Fund
Nifty 5 year Benchmark
G-Sec ETF



Asset Allocation Passive
Fund of Fund - Aggressive
Asset Allocation Passive
Fund of Fund - Conservative



Gold and Silver ETFs
Fund of Funds



Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal Nifty 50 Index Fund (An open ended scheme replicating / tracking Nifty 50 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty 50 Index subject to tracking error Equity and Equity related securities covered by Nifty 50 Index Long-term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty 50 TRI</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal Nifty Next 50 Index Fund (An open ended scheme replicating / tracking Nifty Next 50 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty Next 50 Index subject to tracking error Equity and Equity related securities covered by Nifty Next 50 Index Long-term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty Next 50 TRI</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal Nifty Midcap 150 Index Fund (An open ended scheme replicating / tracking Nifty Midcap 150 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty Midcap 150 Index subject to tracking error Equity and Equity related securities covered by Nifty Midcap 150 Index Long-term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty Midcap 150 TRI</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal Nifty Smallcap 250 Index Fund (An open ended scheme replicating / tracking Nifty Smallcap 250 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty Smallcap 250 Index subject to tracking error Equity and Equity related securities covered by Nifty Smallcap 250 Index Long-term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>Nifty Smallcap 250 TRI</p> <p>Investors understand that their principal will be at very high risk</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
Motilal Oswal Nifty 500 Index Fund (An open ended scheme replicating / tracking Nifty 500 Index)	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty 500 Index subject to tracking error Equity and Equity related securities covered by Nifty 500 Index Long-term capital growth 	Fund 	Nifty 500 TRI
Motilal Oswal Nifty 50 ETF (An open ended scheme replicating/tracking Nifty 50 Index BSE: 590115, NSE: MOM50)	<ul style="list-style-type: none"> Return that corresponds generally to the performance of Nifty 50 Index (Underlying Index), subject to tracking error Investment in equity securities of Nifty 50 Index 	Fund 	Nifty 50 TRI
Motilal Oswal Nifty Midcap 100 ETF (An open ended scheme replicating/tracking Nifty Midcap 100 Index BSE: 536960, NSE: MOM100)	<ul style="list-style-type: none"> Return that corresponds generally to the performance of Nifty Midcap 100 Index subject to tracking error Investment in equity securities of Nifty Midcap 100 Index 	Fund 	Nifty Midcap 100 TRI
Motilal Oswal Nifty Bank Index Fund (An open ended scheme replicating / tracking Nifty Bank Index)	<ul style="list-style-type: none"> Return that corresponds to the performance of Nifty Bank Index subject to tracking error Equity and Equity related securities covered by Nifty Bank Index Long-term capital growth 	Fund 	Nifty Bank TRI

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal S&P 500 Index Fund (An open ended scheme replicating / tracking S&P 500 Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of S&P 500 Index subject to tracking error Investment in equity securities of S&P 500 Index 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>S&P 500 TRI (INR)</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal NASDAQ 100 ETF (An open ended scheme replicating/tracking NASDAQ-100 Index BSE: 533385, NSE: MOFN100)</p>	<ul style="list-style-type: none"> Return that corresponds generally to the performance of NASDAQ 100 Index subject to tracking error Investment in equity securities of NASDAQ 100 Index 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>NASDAQ 100 TRI (INR)</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal NASDAQ 100 Fund of Fund (An open ended fund of fund scheme investing in Motilal Oswal Nasdaq 100 ETF)</p>	<ul style="list-style-type: none"> Long term capital appreciation Return that corresponds to the performance of Motilal Oswal NASDAQ 100 ETF (MON100) Scheme through investment in units of MON100 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>NASDAQ 100 TRI (INR)</p> <p>Investors understand that their principal will be at very high risk</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal Asset Allocation Passive Fund of Fund – Aggressive (An open ended fund of funds scheme investing in passive funds)</p>	<ul style="list-style-type: none"> To generate long term growth/capital appreciation by offering asset allocation Investment solution that predominantly invests in passive funds such as ETF/Index Funds of equity and equity related instruments (domestic as well as international), fixed income and Gold 	<p>Fund</p>	<p>50% Nifty 500 TRI + 20% S&P 500 TRI (INR) + 10% Domestic Price of Gold + 20% Nifty 5 Yr Benchmark G-Sec Index</p>
<p>Motilal Oswal Asset Allocation Passive Fund of Fund – Conservative (An open ended fund of funds scheme investing in passive funds)</p>	<ul style="list-style-type: none"> To generate long term growth/capital appreciation with relatively lower volatility by offering asset allocation Investment solution that predominantly invests in passive funds such as ETF/Index Funds of equity and equity related instruments (domestic as well as international), fixed income and Gold 	<p>Fund</p>	<p>30% Nifty 500 TRI + 10% S&P 500 TRI (INR) + 10% Domestic Price of Gold + 50% Nifty 5 Yr Benchmark G-Sec Index</p>
<p>Motilal Oswal Nifty 5 year Benchmark G-sec ETF (An open ended scheme replicating/tracking Nifty 5 yr Benchmark G-Sec Index) BSE: 543250, NSE: MOGSEC</p>	<ul style="list-style-type: none"> Return that corresponds generally to the performance of Nifty 5 yr Benchmark G-sec Index subject to tracking error Investment in securities of Nifty 5 yr Benchmark G-sec Index 	<p>Fund</p>	<p>Nifty 5 yr Benchmark G-Sec Index</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal 5 Year G-sec FoF (An open ended fund of funds scheme investing in units of Motilal Oswal 5 Year G-Sec ETF)</p>	<ul style="list-style-type: none"> Long term capital appreciation Return that corresponds generally to the performance of the Scheme, Motilal Oswal 5 Year G-Sec ETF through investment in units of Motilal Oswal 5 Year G-Sec ETF 	<p>Fund</p>	<p>Nifty 5 yr Benchmark G-Sec Index</p>
<p>Motilal Oswal MSCI EAFE Top 100 Select Index Fund (An open ended scheme replicating/ tracking MSCI EAFE Top 100 Select Index)</p>	<ul style="list-style-type: none"> Returns that corresponds to the performance of MSCI EAFE Top 100 Select Index, subject to tracking error. Long term capital growth. 	<p>Fund</p>	<p>MSCI EAFE Top 100 Select Index (INR)</p>
<p>Motilal Oswal NASDAQ Q 50 ETF (An open ended scheme replicating/ tracking Nasdaq Q-50 Index BSE: 543437, NSE:MONQ50)</p>	<ul style="list-style-type: none"> Return that corresponds to the performance of the NASDAQ Q-50 TR Index subject to tracking error and forex movement. Long term capital growth. 	<p>Fund</p>	<p>NASDAQ Q-50 Total Return Index (INR)</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal Nifty 200 Momentum 30 ETF (An open ended fund replicating / tracking the Nifty 200 Momentum 30 Total Return Index (BSE: 543465, NSE: MOMOMENTUM))</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the Nifty 200 Momentum 30 Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p>	<p>Nifty 200 Momentum 30 TRI</p>
<p>Motilal Oswal Nifty 200 Momentum 30 Index Fund (An open ended fund replicating / tracking the Nifty 200 Momentum 30 Total Return Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the Nifty 200 Momentum 30 Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p>	<p>Nifty 200 Momentum 30 TRI</p>
<p>Motilal Oswal S&P BSE Low Volatility ETF (An open ended fund replicating / tracking the S&P BSE Low Volatility Total Return Index BSE: 543501, NSE: MOLOWVOL)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Low Volatility Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p>	<p>S&P BSE Low Volatility Total Return Index</p>
<p>Motilal Oswal S&P BSE Low Volatility Index Fund (An open ended fund replicating / tracking the S&P BSE Low Volatility Total Return Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Low Volatility Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p>	<p>S&P BSE Low Volatility Total Return Index</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

For Financial Professionals. Proprietary Content. Permission to reprint or distribute any content from this presentation requires the written approval of Motilal Oswal Asset Management Company.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal S&P BSE Financials ex Bank 30 Index Fund (An open ended fund replicating / tracking the S&P BSE Financials ex Bank 30 Total Return Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Financials ex Bank 30 Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p>	<p>S&P BSE Financials ex Bank 30 Total Return Index</p>
<p>Motilal Oswal S&P BSE Healthcare ETF (An open ended fund replicating / tracking the S&P BSE Healthcare Total Return Index BSE: 543563, NSE: MOHEALTH)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Healthcare Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p>	<p>S&P BSE Healthcare Total Return Index</p>
<p>Motilal Oswal S&P BSE Quality ETF (An open ended fund replicating / tracking the S&P BSE Quality Total Return Index BSE: 543577, NSE: MOQUALITY)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Quality Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p>	<p>S&P BSE Quality Total Return Index</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal S&P BSE Quality Index Fund (An open ended fund replicating / tracking the S&P BSE Quality Total Return Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Quality Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>S&P BSE Quality Total Return Index</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal S&P BSE Enhanced Value ETF (An open ended fund replicating / tracking the S&P BSE Enhanced Value Total Return Index BSE:543576, NSE: MOVALUE)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Enhanced Value Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>S&P BSE Enhanced Value Total Return Index</p> <p>Investors understand that their principal will be at very high risk</p>
<p>Motilal Oswal S&P BSE Enhanced Value Index Fund (An open ended fund replicating / tracking the S&P BSE Enhanced Value Total Return Index)</p>	<ul style="list-style-type: none"> Return that corresponds to the total returns of the S&P BSE Enhanced Value Total Return Index subject to tracking error Long term capital growth 	<p>Fund</p> <p>Investors understand that their principal will be at very high risk</p>	<p>S&P BSE Enhanced Value Total Return Index</p> <p>Investors understand that their principal will be at very high risk</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Product Suitability

Name of the Scheme	This product is suitable for investors who are seeking*	Scheme Riskometer	Benchmark Riskometer
<p>Motilal Oswal Gold and Silver ETFs Fund of Funds (An open ended fund of funds scheme investing in units of gold and silver exchange traded funds)</p>	<ul style="list-style-type: none"> Return that corresponds generally to the performance of the underlying Schemes of Gold ETF and Silver ETF Long term capital appreciation 	<p style="text-align: center;">Fund</p>	<p style="text-align: center;">LBMA Price of Gold and Silver</p>

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

Thank You

“ You should have a strategic asset allocation mix that assumes that you don’t know what the future is going to hold”

- By Ray Dalio

Contact Us -

Speak: +91-22 40548002 | 8108622222

Write: mfservice@motilaloswal.com

Visit: www.motilaloswalmf.com

Disclaimers & Risk Factors



This presentation has been prepared and issued on the basis of internal data, publicly available information and other sources believed to be reliable. The information contained in this document is for general purposes only and not a complete disclosure of every material fact and terms and conditions. The information / data herein alone is not sufficient and shouldn't be used for the development or implementation of an investment strategy. It should not be construed as investment advice to any party.

All opinions, figures, charts/graphs, estimates and data included in this presentation are as on date and are subject to change without notice. The statements contained herein may include statements of future expectations and other forward-looking statements that are based on our current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Readers shall be fully responsible / liable for any decision taken on the basis of this presentation. Investments in Securities are subject to market and other risks and there is no assurance or guarantee that the objectives of any of the Schemes will be achieved. The scheme may not be suited to all categories of investors.

The material is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Opinions, if any, expressed are our opinions as of the date of appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Recipient shall understand that the aforementioned statements cannot disclose all the risks and characteristics. The recipient is requested to take into consideration all the risk factors including their financial condition, suitability to risk return, etc. and take professional advice before investing.

Risks associated with investing in Equities

Investments in the equity shares of the Companies constituting the Underlying Index are subject to price fluctuation on daily basis. The volatility in the value of equity is due to various micro and macro-economic factors like economic and political developments, changes in interest rates, etc. affecting the securities markets. This may have adverse impact on individual securities/sector and consequently on the NAV of Scheme.

Passive Investments -

The Fund would invest in the Index/ETF Schemes regardless of investment merit, research, without taking a view of the market and without adopting any defensive measures. The Fund would not select securities in which it wants to invest but is guided by the Underlying Index/ETF Schemes. As such the Scheme is passively managed.

Risk associated with investing in Foreign Securities

The risk of investing in foreign securities carries an exchange rate risks related to depreciation of foreign currency and country risks. The country risks would include events such as change in regulations or political circumstances like introduction of extraordinary exchange rate controls, restrictions on repatriation of capital due to exchange rate controls, bilateral political tensions leading to immobilisation of overseas financial assets and the prevalent tax laws of the respective jurisdiction for the execution of trades or otherwise. The Scheme may invest in the units of overseas mutual fund schemes including exchange traded funds. Hence scheme specific risk factors of such underlying schemes will be applicable. Investors who intend to invest in the Scheme are required to and deemed to have understood the risk factors of the underlying schemes.

Risk associated with investing in fixed income securities and Money Market Instruments

The Fund may be exposed to credit risk which may arise due to default on the part of the issuer of the fixed income security (i.e. will be unable to make timely principal and interest payments on the security). Because of this risk debentures are sold at a yield spread above those offered on Treasury securities, which are sovereign obligations and generally considered to be free of credit risk. Normally, the value of a fixed income security will fluctuate depending upon the actual changes in the perceived level of credit risk as well as the actual event of default. Further, losses can occur in particular for the settlement/delivery of financial instruments. Further, the scheme may be exposed to liquidity or marketability Risk which refers to ease at which a security can be sold at or near its true value.

Risk associated with investments in Gold ETF's:

The scheme would invest in Gold ETFs and thus the NAV of the scheme will react to Gold price movements. Several factors that may affect the price of gold are as follows:

- Global gold supplies and demand, which is influenced by factors such as forward selling by gold producers, purchases made by gold producers to unwind gold hedge positions, central bank purchases and sales, productions and cost levels in major gold producing countries such as the South Africa, the United States and Australia.
- Investors' expectations with respect to the rate of inflation
- Currency exchange rates
- Interest rates
- Investment and trading activities of hedge funds and commodity funds
- Global or regional political, economic or financial events and situations
- Changes in indirect taxes or any other levies

For detailed risk factors, investors are requested to refer the SID.

Investors are requested to note that they will be bearing the recurring expenses of the fund of funds (FoF) scheme, in addition to the expenses of underlying schemes in which the fund of funds scheme makes investments.

Mutual Fund Investments are subject to market risks, read all scheme related documents carefully

For Financial Professionals. Proprietary Content. Permission to reprint or distribute any content from this presentation requires the written approval of Motilal Oswal Asset Management Company.

Disclaimers & Risk Factors



NSE Indices Limited Disclaimer: MOFM50 and MOFM100: MOFM50 and MOFM100 offered by Motilal Oswal Asset Management Company Limited (MOAMC) or its affiliates is not sponsored, endorsed, sold or promoted by NSE Indices Limited and its affiliates. NSE Indices Limited and its affiliates do not make any representation or warranty, express or implied (including warranties of merchantability or fitness for particular purpose or use) to the owners of MOFM50 and MOFM100 or any member of the public regarding the advisability of investing in securities generally or in the MOFM50 and (MOFM100) linked to Nifty 50 Index and Nifty Midcap 100 Index respectively or particularly in the ability of Nifty 50 Index and Nifty Midcap 100 Index to track general stock market performance in India. Please read the full Disclaimers in relation to the Nifty 50 Index and Nifty Midcap 100 Index in the Scheme Information Document. Motilal Oswal 5 Yr G-Sec ETF is offered by Motilal Oswal Asset Management Company Limited (MOAMC) or its affiliates is not sponsored, endorsed, sold or promoted by NSE Indices Limited and its affiliates. NSE Indices Limited and its affiliates do not make any representation or warranty, express or implied (including warranties of merchantability or fitness for particular purpose or use) to the owners of Motilal Oswal 5 Yr G-Sec ETF or any member of the public regarding the advisability of investing in securities generally or in the Motilal Oswal 5 Yr G-Sec ETF linked to Nifty 5 Yr Benchmark G-Sec Index or particularly in the ability of Nifty 5 Yr Benchmark G-Sec Index to track general G-Sec performance in India. Please read the full Disclaimers in relation to the Nifty 5 Yr Benchmark G-Sec Index in the Scheme Information Document.

The **S&P 500 Index** is a product of S&P Dow Jones Indices LLC or its affiliates (“SPDJI”) have been licensed for use by Motilal Oswal Asset Management Company Limited (MOAMC) . Standard & Poor’s® and S&P® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”); **Motilal Oswal S&P Index Fund (MOFSP500)** is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the **S&P 500 Index**.

The **S&P 500 Index** is a product of S&P Dow Jones Indices LLC or its affiliates (“SPDJI”) have been licensed for use by MOAMC. Standard & Poor’s® and S&P® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”); It is not possible to invest directly in an index. **MOFSP500** is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, any of their respective affiliates (collectively, “S&P Dow Jones Indices”) S&P Dow Jones Indices does not make any representation or warranty, express or implied, to the owners of the **MOFSP500** or any member of the public regarding the advisability of investing in securities generally or in **MOFSP500** particularly or the ability of the **S&P 500 Index** to track general market performance. Past performance of an index is not an indication or guarantee of future results. S&P Dow Jones Indices’ only relationship to **MOAMC** with respect to the **S&P 500 Index** is the licensing of the Index and certain trademarks, service marks and/or trade names of S&P Dow Jones Indices and/or its licensors. The **S&P 500 Index** is determined, composed and calculated by S&P Dow Jones Indices without regard to **MOAMC** or the **MOFSP500**. S&P Dow Jones Indices have no obligation to take the needs of **MOAMC** or the owners of **MOFSP500** into consideration in determining, composing or calculating the **S&P 500 Index**. S&P Dow Jones Indices is **not** responsible for and has not participated in the determination of the prices, and amount of **MOFSP500** or the timing of the issuance or sale of **MOFSP500** or in the determination or calculation of the equation by which **MOFSP500** is to be converted into cash, surrendered or redeemed, as the case may be. S&P Dow Jones Indices have no obligation or liability in connection with the administration, marketing or trading of **MOFSP500**. There is no assurance that investment products based on the **S&P 500 Index** will accurately track index performance or provide positive investment returns. S&P Dow Jones Indices LLC is not an investment or tax advisor. A tax advisor should be consulted to evaluate the impact of any tax-exempt securities on portfolios and the tax consequences of making any particular investment decision. Inclusion of a security within an index is not a recommendation by S&P Dow Jones Indices to buy, sell, or hold such security, nor is it considered to be investment advice.

NEITHER S&P DOW JONES INDICES NOR THIRD PARTY LICENSOR GUARANTEES THE ADEQUACY, ACCURACY, TIMELINESS AND/OR THE COMPLETENESS OF THE **S&P 500 Index** OR ANY DATA RELATED THERETO OR ANY COMMUNICATION, INCLUDING BUT NOT LIMITED TO, ORAL OR WRITTEN COMMUNICATION (INCLUDING ELECTRONIC COMMUNICATIONS) WITH RESPECT THERETO. S&P DOW JONES INDICES AND **SHALL** NOT BE SUBJECT TO ANY DAMAGES OR LIABILITY FOR ANY ERRORS, OMISSIONS, OR DELAYS THEREIN. S&P DOW JONES INDICES AND MAKES NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE OR AS TO RESULTS TO BE OBTAINED BY **MOAMC**, OWNERS OF **MOFSP500**, OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE **S&P 500 Index** OR WITH RESPECT TO ANY DATA RELATED THERETO. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT WHATSOEVER SHALL S&P DOW JONES INDICES BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES INCLUDING BUT NOT LIMITED TO, LOSS OF PROFITS, TRADING LOSSES, LOST TIME OR GOODWILL, EVEN IF THEY HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, WHETHER IN CONTRACT, TORT, STRICT LIABILITY, OR OTHERWISE. THERE ARE NO THIRD PARTY BENEFICIARIES OF ANY AGREEMENTS OR ARRANGEMENTS BETWEEN S&P DOW JONES INDICES AND **MOAMC**, OTHER THAN THE LICENSORS OF S&P DOW JONES INDICES

Disclaimers & Risk Factors



NASDAQ OMX Group, Inc.

The Product i.e. MOFN100 is not sponsored, endorsed, sold or promoted by The NASDAQ OMX Group, Inc. or its affiliates (NASDAQ OMX, with its affiliates, are referred to as the "Corporations"). The Corporations have not passed on the legality or suitability of, or the accuracy or adequacy of descriptions and disclosures relating to, the Product. The Corporations make no representation or warranty, express or implied to the owners of the Product or any member of the public regarding the advisability of investing in securities generally or in the Product particularly, or the ability of the Nasdaq-100 Index[®] to track general stock market performance. The Corporations' only relationship to Motilal Oswal Asset Management Company Ltd. ("Licensee") is in the licensing of the NASDAQ[®], OMX[®], NASDAQ OMX[®], NASDAQ-100[®], and NASDAQ-100 Index[®] registered trademarks, and certain trade names of the Corporations and the use of the NASDAQ-100 Index[®] which is determined, composed and calculated by NASDAQ OMX without regard to Licensee or the Product. NASDAQ OMX has no obligation to take the needs of the Licensee or the owners of the Product(s) into consideration in determining, composing or calculating the NASDAQ-100 Index[®]. The Corporations are not responsible for and have not participated in the determination of the timing of, prices at, or quantities of the Product to be issued or in the determination or calculation of the equation by which the Product is to be converted into cash. The Corporations have no liability in connection with the administration, marketing or trading of the Product.

THE CORPORATIONS DO NOT GUARANTEE THE ACCURACY AND/OR UNINTERRUPTED CALCULATION OF THE NASDAQ-100 INDEX[®] OR ANY DATA INCLUDED THEREIN. THE CORPORATIONS MAKE NO WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY LICENSEE, OWNERS OF THE PRODUCT(S), OR ANY OTHER PERSON OR ENTITY FROM THE USE OF THE NASDAQ-100 INDEX[®] OR ANY DATA INCLUDED THEREIN. THE CORPORATIONS MAKE NO EXPRESS OR IMPLIED WARRANTIES, AND EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE WITH RESPECT TO THE NASDAQ-100 INDEX[®] OR ANY DATA INCLUDED THEREIN. WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL THE CORPORATIONS HAVE ANY LIABILITY FOR ANY LOST PROFITS OR SPECIAL, INCIDENTAL, PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES, EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

BSE

The Bombay Stock Exchange Limited ("the Exchange") has given vide its letter dated February 10, 2011 permission to the Mutual Fund to use the Exchange's name in this Scheme Information Document as one of the stock exchanges on which the Mutual Fund's units are proposed to be listed subject to, the Mutual Fund fulfilling the various criteria for listing. The Exchange has scrutinized this Scheme Information Document for its limited internal purpose of deciding on the matter of granting the aforesaid permission to the Mutual Fund. The Exchange does not in any manner:-

1. warrant, certify or endorse the correctness or completeness of any of the contents of this SID;
2. warrant that the Mutual Fund's units will be listed or will continue to be listed on the Exchange;
3. take any responsibility for the financial or other soundness of the Mutual Fund, its sponsors, its promoters, its management or any scheme or project of this Mutual Fund.

and should not for any reason be deemed or construed that the Scheme Information Document has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquire any units of Motilal Oswal NASDAQ-100 (MOFN100) of this Mutual Fund may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by such person consequent to or in connection with such subscription /acquisition whether by reason of anything stated or omitted to be stated herein or any other reason whatsoever.